Fig. 6.

Western blot analysis of autophagy markers in platinum sensitive M019i and resistant M019iCis cells. In addition to untreated samples (0 μmol/L) M019i cells were treated with cisplatin at IC₅₀ (0.6 μmol/L) while M019iCis cells were treated with IC₅₀ of both cell lines (0.6 μmol/L or 7 μmol/L; IC₅₀ of M019iCis). Two-Way ANOVA with multiple comparisons using posthoc Tukey test was used to evaluate statistical differences between paired treatment groups of sensitive and resistant cells. One-Way ANOVA with multiple comparisons using posthoc Holm-Sidak method was used to compare treatment groups of resistant cell line. Each bar shows mean ± S.E. of three separate experiments. *p < 0.05, ** p < 0.01, *** p < 0.001. A, SQSTM1, (B) Atg7, (C) Atg5 bound to atg12, (D) LC3-I, (E) LC3-II, (F) LC3-II/LC3-I, (G) Relative viability of platinum resistant cells in presens of cisplatin (10 μmol/L), 3-MA (5 mmol/L) or both.